Abbott Laboratories $ABT Shares Bought by Dundas Partners LLP

Dundas Partners LLP grew its holdings in shares of Abbott Laboratories (NYSE:ABT) by 19.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 442,954 shares of the healthcare product maker’s stock after purchasing an additional 71,239 shares during the period. Abbott Laboratories accounts for 4.2% of Dundas Partners LLP’s portfolio, making the stock its 9th biggest position. Dundas Partners LLP’s holdings in Abbott Laboratories were worth $59,329,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of ABT. Carr Financial Group Corp grew its position in shares of Abbott Laboratories by 2.0% during the third quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock worth $520,000 after acquiring an additional 76 shares during the last quarter. Tortoise Investment Management LLC lifted its position in Abbott Laboratories by 10.7% in the second quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock worth $108,000 after purchasing an additional 77 shares during the period. Gemmer Asset Management LLC grew its holdings in Abbott Laboratories by 2.9% during the third quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock worth $368,000 after acquiring an additional 78 shares during the period. Global Financial Private Client LLC grew its stake in shares of Abbott Laboratories by 3.3% in the 3rd quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock worth $331,000 after purchasing an additional 79 shares during the last quarter. Finally, Citizens & Northern Corp grew its position in Abbott Laboratories by 0.4% in the third quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker’s stock worth $2,930,000 after buying an additional 79 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 585 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the transaction, the vice president owned 24,628 shares in the company, valued at approximately $2,846,504.24. This represents a 2.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The stock was purchased at an average cost of $108.73 per share, for a total transaction of $1,087,300.00. Following the transaction, the director owned 6,738,817 shares in the company, valued at $732,711,572.41. The trade was a 0.15% increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold 3,055 shares of company stock worth $353,097 over the last ninety days. Insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Piper Sandler reduced their price target on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a research report on Friday, January 23rd. Citigroup reduced their target price on shares of Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. The Goldman Sachs Group cut their target price on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Leerink Partners lowered their price objective on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a report on Friday, January 30th. Finally, Evercore cut their price objective on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $137.05.

Abbott Laboratories Trading Down 1.2%

Shares of ABT opened at $109.74 on Monday. The stock has a 50 day simple moving average of $116.09 and a 200-day simple moving average of $124.57. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The stock has a market cap of $190.69 billion, a PE ratio of 29.50, a PEG ratio of 1.74 and a beta of 0.74. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $139.15.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same period in the previous year, the business earned $1.34 EPS. Abbott Laboratories’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is 67.74%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.